Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis

Abstract

Human chromosome 9p21.3 is susceptible to inactivation in cell immortalization and diseases, such as cancer, coronary artery disease and type-2 diabetes. Although this locus encodes three cyclin-dependent kinase (CDK) inhibitors (p15^INK4B, p14^ARF and p16^INK4A), our understanding of their functions and modes of action is limited to the latter two. Here, we show that in vitro p15^INK4B is markedly stronger than p16^INK4A in inhibiting pRb1 phosphorylation, E2F activity and cell-cycle progression. In mice, urothelial cells expressing oncogenic HRas and lacking p15^INK4B, but not those expressing HRas and lacking p16^INK4A, develop early-onset bladder tumors. The potency of CDKN2B/p15^INK4B in tumor suppression relies on its strong binding via key N-terminal residues to and inhibition of CDK4/CDK6. p15^INK4B also binds and inhibits enolase-1, a glycolytic enzyme upregulated in most cancer types. Our results highlight the dual inhibition of p15^INK4B on cell proliferation, and unveil mechanisms whereby p15^INK4B aberrations may underpin cancer and non-cancer conditions.